Home > Insider Trading > Filing (0001209191-21-009627)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
818686	Teva Pharmaceutical Industries Ltd	TEVA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1726096	Richard Daniell	C/O Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva L3 4951033	Exec. Vp, European Commercial	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2021-02-09	13,135	$0.00	23,900	No	4	M	Direct
Ordinary Shares	Acquisiton	2021-02-09	55,287	$0.00	79,187	No	4	A	Direct
Ordinary Shares	Disposition	2021-02-09	13,135	$12.72	66,052	No	4	S	Direct
Ordinary Shares	Disposition	2021-02-09	55,287	$12.72	10,765	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Share Units	Disposition	2021-02-09	13,135	$0.00	13,135	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,135			No	4	M	Direct

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.
Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9,2022.